Background: Signaling pathways involved in the sensitization by target receptors of ␤-amyloid-triggered neurotoxicity have not been identified. Results: Exposure to ␤-amyloid in the presence of nicotinic receptors led to ERK activation followed by JNK activation and increased PHF-tau. Conclusion: ␤-amyloid neurotoxicity entails activation of discrete intracellular signaling pathways. Significance: Activation of select signaling pathways by ␤-amyloid may be an early event in Alzheimer disease.
Alzheimer disease (AD) 2 is a progressive neurodegenerative disorder. It is characterized by various pathological hallmarks including extracellular plaques composed primarily of beta amyloid (A␤), intracellular neurofibrillary tangles formed from hyperphosphorylated tau, synaptic loss, and neurodegeneration in brain regions critical for memory processes. The onset of AD is best correlated with increased levels of A␤ (1) . There exists evidence indicating that various different intracellular pathways including MAP kinases (MAPK), Fyn and others can be acutely regulated by oligomeric A␤ (2) . The roles for these pathways in AD remain to be determined.
All MAPK pathways (the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 pathways) appear to have been activated in vulnerable neurons by A␤ (2), suggesting involvement in the pathophysiology and pathogenesis of AD. Studies conducted on post-mortem tissues have confirmed that the activation of MAPK occurs at a very early stage in AD (3, 4) . In model neuronal systems, ERK and one of its downstream effectors CREB (cyclic AMP-regulatory element binding) were activated by A␤ in a manner dependent on calcium and nAChRs (5, 6) . Notably, A␤ activation of the ERK pathway has been linked to caspase activation (7) and the pathological hyper-phosphorylation of tau. Studies have also demonstrated that A␤ can regulate CREB and Ca 2ϩ / calmodulin-dependent kinase II (CaMKII) by activating calcineurin and protein phosphatase 1, leading to deficits in longterm potentiation (LTP) in the hippocampus (8) . ERK/CREB signaling in the hippocampus normally plays a significant role in determining LTP (9, 10) . Hence, contextual and spatial memory formation in mammals (11) (12) (13) (14) resulting from alterations in ERK signaling by A␤ may contribute to early memory deficits in AD.
A possible link between the JNK signaling pathway and A␤-induced oxidative stress has been implicated in neuronal compromise (15) (16) . Indeed, inhibitors for JNK, as well as ERK1/2, and the upstream regulators MEKs (MAP2Ks) have been widely investigated as potential therapeutic drugs for AD (e.g. 17, 18) . Interestingly, MAPK signaling is regulated by a group of MAP kinase phosphatases (MKPs) (19) , specifically, the dual-specificity MKPs, which can differentially regulate ERK and JNK (20) .
In parallel, Fyn, a member of the Src family of kinases, plays a role in the regulation of A␤ production as well as A␤-induced synaptic deficits and neurotoxicity, perhaps primarily by inducing tyrosine phosphorylation of tau (21) . The relation of this signaling pathway to the MAPK pathway in AD remains unclear.
As we have previously found that the presence of a relatively high-affinity target receptor for A␤ sensitizes nerve cells to A␤ toxicity (22) , potential roles for select intracellular pathways involved in this sensitization were evaluated. The study focused on the MAPK pathway, assessing the relationship between receptor-linked, A␤-induced alterations in signaling and oxidative stress.
Experimental Procedures
Cell Culture and Transfection-Hybrid neuroblastoma NG108 -15 cells were used as a model nerve cell system, as they are normally devoid of functional nAChRs (22) (23) (24) . The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 15% FBS and hypoxanthine/aminopterin/ thymidine (HAT selection). Cells were differentiated on poly-L-lysine (plates) or Cell-Tak (coverslips) with 1 mM dibutyryl cyclic AMP in DMEM in the presence of reduced serum (1% FBS) and penicillin-streptomycin-glutamine for 72 h, as described previously (22) (23) (24) . pcDNA3.1 expression vectors harboring mouse sequences for ␣4 and ␤2 nAChR subunits (1:4 ratio, respectively) were transfected into the differentiated cells using FuGENE HD, a lipid-based transfection reagent, for 48 h. Mock-transfected NG108 -15 cells, exposed only to FuGENE HD and not plasmid DNA, were used as controls (22) (23) (24) .
Immunoblot Analysis-NG108 -15 cells were grown and differentiated on poly-L-lysine-coated 10-cm cell culture plates as previously described. Forty-eight hours after transfection, the cells were treated with 100 nM A␤ 1-42 for different time-points ranging from 30 min to 3 days in the presence or absence of particular inhibitors. To further distinguish the effects produced by interaction between A␤ 1-42 and ␣4␤2 nAChRs, mock-transfected cells (untreated or A␤-treated) were used as controls. The medium was aspirated, and the cells were washed with PBS. After adding 100 l of lysis buffer (25 mM HEPES, 200 mM NaCl, 1 mM EDTA, 0.5% digitonin, 0.2% sodium cholate, 0.5% Nonidet P-40, HaltTM Protease Inhibitor Mixture, 0.02% DTT), the cells were scraped gently from the plates sitting on ice and collected in a microcentrifuge tube. The plates were washed with another 100 l of lysis buffer for maximum cell recovery. The extracted proteins were collected by centrifugation at 13,000 rpm for 20 min at 4°C. The pellet was discarded and the supernatant (protein) was collected in a fresh microcentrifuge tube. The protein samples were then diluted with 25 l of SDS sample buffer and 10 l dithiothreitol to make a total volume of 100 l. The samples were heated to 95°C for 5 min, cooled immediately on ice, and then centrifuged. Equal amounts of protein were loaded onto 4 -20% Tris-HCl gels and the samples resolved by SDS-PAGE. Proteins were then transferred to preactivated PVDF membrane using the Invitrogen iBlot semi-dry blotting system. Membranes were preactivated by incubating with methanol for 30 s, washing with distilled water for 2 min, and adding transfer buffer for 30 min. After transfer, membranes were soaked in PBS for 5 min and incubated with LI-COR blocking buffer for 2 h at room temperature with shaking. The membranes were then separately incubated with various primary antibodies at dilutions of 1:1000 overnight at 4°C with gentle shaking. The membranes were washed three times for 10 min each with TBS containing 0.1% Tween (TBST). Bound primary antibodies were detected via IR dye-linked LI-COR secondary antibodies (anti-mouse, anti-rabbit, or anti-rat; 1:5000) for 1 h at room temperature followed by washing the membrane three times with TBST for 10 min each. Immunoreactivity for actin or GAPDH was used as a loading control. Immunoreactive bands in the PVDF membrane were visualized using an Odyssey Infrared Imaging system (LI-COR Biosciences). Bands were compared with protein standards.
Immunocytochemistry-Cells were differentiated on Cell-Tak-coated coverslips and transfected as described (22) (23) (24) . After various treatments, cells were fixed using freshly prepared 4% paraformaldehyde for 40min and rinsed with PBS for 30 min. To block nonspecific binding, the fixed cells were incubated in TBS containing 5% BSA and 10% normal goat serum for 30 min. Rabbit anti-pERK1/2 and mouse anti-ERK1/2 (1:200) were then added to the cultures and incubated overnight at 4°C. The cultures were then washed with 10% goat serum in TBS for 30 min, and thereafter, incubated with the fluorescent secondary antibodies (anti-rabbit Alexa-488 and anti-mouse Alexa-633 IgGs, respectively; 1:500) for 30 min at room temperature. The coverslips were finally washed with 10% normal goat serum and TBS, plated onto glass microscope slides and sealed for imaging using a Zeiss LSM 5 Pascal confocal imaging system on a Zeiss Axiovert 200M microscope or a Nikon Cameleon AOTF confocal system.
Reactive Oxygen Species (ROS)/Hoechst Staining-Relative oxidative stress was assessed in live cultures of differentiated cells, transfected as described (22) , as changes in the levels of reactive molecular species. Following various treatments, the Image-iT Live Reactive Oxygen Species Detection assay (Life Technologies) was performed in accordance with the manufacturer's protocol. In brief, the cells were incubated with carboxy-H 2 DCFDA (component A) at 37°C for 30 min. During the last 5 min of incubation, 2 g/ml of HOECHST stain (component B) was added. The cells were washed twice with HBS and visualized using an Olympus IX71 epifluorescence microscope at excitation/emission of 495/529 nm (ROS) and 350/461 nm (HOECHST), respectively, linked to a Macrofire camera.
A␤-A␤ 1-42 was purchased from American Peptide. A stock solution (0.1 mM) of A␤ 1-42 was prepared by dissolving the solid peptide in double-de-ionized water. The solution was vortexed and sonicated for 15 min to ensure complete solubilization (see Ref. 23 ). Under these conditions, A␤ 1-42 is largely present as stable oligomers, as assessed by SDS-PAGE and native gel analysis (6, 23).
Chemicals-DMEM was from Mediatech, Inc. FBS and normal goat serum were from GIBCO. Cell-Tak was from BD Biosciences (Bedford, MA). Poly-L-lysine was from Sigma. Image iT Live ROS Detection kit was purchased from Life Technologies. Paraformaldehyde was from Fisher. BSA was purchased from Sigma-Aldrich. Anti-phosphoERK, anti-panERK, anti-phosphoJNK, anti-panJNK, anti-phosphoCREB, and anti-phosphoMARCKS were all from Cell Signaling. Anti-phospho-Fyn was from BD Transduction Labs. Anti-PHF tau (clone AT8), anti-phosphoCaMKII and anti-panCaMKII were from ThermoFisher (Pierce). Anti-MKP7 was from Santa Cruz Biotechnology. Anti-actin was from Sigma; anti-GAPDH was from Abcam. The FITC-labeled and peroxidase-conjugated secondary antibodies (goat anti-rabbit and goat anti-mouse) were from Jackson ImmunoResearch. The Alexa-488 and Alexa-633 secondary antibodies were purchased from Life Technologies. IRDye 680 goat anti-rabbit secondary antibod-ies were from LI-COR. U0126 was from Cell Signaling, while DJNK-1 was the kind gift of Dr. Tessi Sherrin (University of Hawaii). Both reagents were used at concentrations effecting full inhibition, as based on previous reports (25) . All common reagents (e.g. buffers, salts, solvents, detergents, etc.) were either from ThermoFisher or Sigma-Aldrich.
Statistical Analysis-Multiple comparisons were subjected to ANOVA, followed by Bonferroni posthoc tests. A minimum of p Ͻ 0.05 was used to establish a significant difference. All experiments were replicated at least 3 times.
Results
Differential Activation of MAPK Pathways following Sustained Exposure of Neuronal Cultures Expressing ␣4␤2-nAChRs to A␤-We have previously shown that the presence of ␣4␤2-nAChRs sensitizes the cells to toxicity induced by prolonged exposure to A␤, as measured by increased ROS produc-FIGURE 1. Activation of the ERK MAPK pathway in NG108 -15 cells expressing ␣4␤2 nAChRs in response to prolonged exposure to A␤: time-dependence and sensitivity to a MEK inhibitor. A and B, progressive increases in pERK levels in response to prolonged exposure to 100 nM A␤ in the absence or presence of U1026, a selective inhibitor of MEK, the upstream regulator of ERK, in cells expressing ␣4␤2-nAChRs or not (Mock: mock-transfected). pERK levels were compared with total ERK as well as actin (loading control). Data are expressed as % (Ϯ S.E.) of untreated, mock-transfected controls (n ϭ 3 experiments). C, representative images depicting immunostaining of pERK and total ERK in mock-and ␣4␤2-nAChR-transfected cells treated with A␤ 1-42 for 3 days. pERK levels in cells expressing ␣4␤2-nAChRs and treated with A␤ were significantly different in comparison to untreated controls. tion, decreased nuclear integrity, and eventual cell death (22) . To investigate the initial downstream effects of receptor-coupled sensitization of A␤ 1-42 toxicity, differentiated NG108 -15 cells expressing ␣4␤2-nAChRs were exposed to fresh, oligomeric A␤ 1-42 at 100 nM (22) for several time-points from 30 min, 1 h, 6 h, 12 h, 1 d, 1.5 d, 2 to 3 days. Mock-transfected cells treated with A␤ 1-42 for 0 and 3 days were used as controls. Cell lysates were analyzed via immunoblotting using rabbit antiphospho-ERK1/2 and mouse anti-ERK1/2 (pan) antibodies. Whereas little if any activation was observed in mock-transfected cells treated with 100 nM A␤ 1-42 for 3 days, the levels of pERK1 as well as pERK2 were strongly up-regulated in a timedependent manner in cells transfected with ␣4␤2-nAChRs, increasing severalfold by 2-3 days, (Fig. 1, A and B ; p Ͻ 0.001 compared with mock-transfected controls). The cells expressing ␣4␤2-nAChRs had basal levels (t 0 ) of pERK1/2 comparable to the levels found in mock-transfected cells treated with A␤ 1-42 for 3 days. Interestingly, an A␤-induced increase in pERK1 and pERK2 was detectable at 30min out to 12 h for ␣4␤2-nAChR-transfected cells (p Ͻ 0.05 compared with baseline), indicating that activation of ERK is a very early event. The increase in pERK induced by A␤ was inhibited upon co-incubation with U0126, a specific MEK1/2 inhibitor (ERK is downstream of MEK1/2), as assessed by both immunoblot analysis ( Figs. 1A and B) and immunostaining (Fig. 1C) . The selectivity for ERK activation via ␣4␤2-nAChRs is in accordance with the studies using a transgenic AD mouse model (Tg2576), which showed an age-dependent increase both in nAChR expression as well as in ERK2 activation in the hippocampus and the cortex (5). A similar effect was observed using organotypic hippocampal slices incubated with A␤ (5).
The phosphorylated forms of JNK, another member of the MAPK family, was found to be significantly up-regulated as a result of A␤ 1-42 exposure, starting at 1 day and then substantially increasing at 2-3 days. This up-regulation was fully blocked by co-incubation with the JNK peptide inhibitor, DJNK-1 ( Fig. 2A) . However, the increase in the levels of the neuronal isoforms of pJNK2,3 was dramatically more pronounced than that of pJNK1: over 5-fold as compared around 2-fold, respectively, by 3 days in the presence of the ␣4␤2-nAChRs (Fig. 2B) . The basal levels of pJNK1-3 were nominally higher in ␣4␤2-nAChR-transfected cells as compared with mock-transfected cells. This up-regulation is consistent with the recent studies demonstrating the neuroprotective effect of inhibiting JNK activity in rodent AD models (26, 27) .
As MAPK phosphatases (MKPs) regulate MAPK signaling, we determined the levels of MKP in cells treated with A␤. A␤-induced up-regulation of ERK and JNK was accompanied by a significant reduction in the levels of MKPs, especially MKP-7, which is JNK-specific (MKP-7, Fig. 2, C and D; MKP-1 , not shown), indicating that decreased phosphatase activity may, in part, contribute to the MAPK activation. Under the conditions of the present study, there was no consistent up- regulation of p38 MAPK with prolonged exposure of differentiated NG108 -15 cells expressing nAChRs (data not shown).
To investigate possible cross-talk between the ERK and JNK pathways, we determined the levels of pERK1/2 against total ERK in cells expressing ␣4␤2-nAChRs and treated or not with A␤ in the presence of the JNK inhibitor DJNK-1. The levels of pERK1/2 were significantly attenuated (Fig. 3, A and B) , particularly after 1d of treatment. A similar trend was observed for pJNK levels when the ␣4␤2-nAChR-expressing cells were co-treated with A␤ 1-42 and the MEK inhibitor U0126 (Fig. 3, A and  C) . The markedly decreased up-regulation suggests a partial interplay between the two pathways.
MAPK Pathways in A␤-induced Oxidative Stress-To test the role of MAPK in the sensitization by ␣4␤2-nAChRs of A␤-induced toxicity, specifically oxidative stress, we determined the levels of ROS and nuclear integrity in the cells, untreated (control), or treated with 100 nM A␤ 1-42 for 3 days in the presence or absence of U0126 (MEK inhibitor) or DJNK-1 FIGURE 3 . Interplay between ERK and JNK pathways activated in cells expressing ␣4␤2 nAChRs in response to prolonged exposure to A␤. A, the levels of pERK1/2 were attenuated in response to prolonged exposure to 100 nM A␤ in the presence of DJNK1, a selective inhibitor of JNK, in cells expressing ␣4␤2-nAChRs. Similarly, levels of pJNK1 as well as pJNK2,3 were reduced significantly on incubation with U1026, MEK inhibitor. B and C represent the quantification of averaged immunoblot intensities for pERK normalized to total ERK and pJNKs normalized to total JNK, as compared with actin (loading control), respectively. *, p Ͻ 0.05 compared with controls not treated with A␤.
(JNK inhibitor) or both. Co-treatment with U0126 or DJNK-1 attenuated the number of ROS-positive cells to ϳ15% of the values found in the absence of the inhibitors (Fig. 4, A and B) over baseline. A similar trend was observed for the number of disintegrated nuclei (Fig. 4, A and C) . Treatment with U0126 or DJNK-1 alone, as separate controls or even co-treatment with both the inhibitors together with A␤, blocked any significant ROS in either mock or ␣4␤2-nAChR-transfected cells.
Regulation of PHF-tau and pFyn following Sustained Exposure of Neuronal Cultures Expressing ␣4␤2-nAChRs to A␤-Mislocalization of hyperphosphorylated tau (and, consequently, PHF-tau) has been widely proposed to be a downstream effector of A␤ toxicity (28, 29) . In addition, recent evidence proposes that the pathological mislocalization of tau is correlated with targeting of Fyn to postsynaptic sites at CA1 synapses (30) . In accordance with these reports, our studies showed that incubation with A␤ caused a significant up-regulation in the levels of both pFyn and PHF-tau ( Fig. 5) , which paralleled the time course for MAPK activation. However, the induction of pFyn was nAChR-independent, whereas the extent of the induction of PHF-tau was receptor-dependent. These data suggest that while Fyn may be important if not essential for tau pathology, it is not involved in the nAChR sensitization of A␤-mediated toxicity.
Altered Levels of pCaMKII and pCREB in Comparison to pMARCKS on Prolonged Incubation of Cells Expressing ␣4␤2-nAChRs to A␤-Activation of nAChRs have been shown to trigger, in turn, the calcium-dependent activation of CaMKII/IV, ERK/MAPK, and CREB in several neuronal models (31) (32) (33) (34) (35) . Based on these studies and our findings showing altered calcium responses in ␣4␤2-nAChR-transfected cells exposed to A␤ for 3 days (22), we also assessed changes in the levels of CaMKII under same conditions. As expected, the levels of phospho-CaMKII were initially increased at 30 min of A␤ exposure and maintained steady state levels up to 12 h. However, the levels rose up again starting at 1day, indicating that the induction in pCaMKII by A␤ has two phases, with the later phase delayed as compared with pERK. Overall, the expression of pCaMKII appeared to be modest.
Levels of phospho-CREB, a downstream effector of ERK and CaMKII, were shown to increase at a much later time point around day 2-3 in cells expressing ␣4␤2-nAChR, following the second phase increase in pCaMKII (Fig. 6C ). There was a slight increase in pCREB levels in mock-transfected cells exposed to A␤. Unlike pERK and CaMKII, pCREB was not significantly increased at 30 min.
For comparison, alterations in pMARCKS, identified in a preliminary proteomics screen following A␤ treatment, was examined to assess the involvement of the parallel PKC pathway. There was actually a decrease in pMARCKs in receptorexpressing cells as compared with controls (mock-transfected) in response to prolonged A␤ exposure (Fig. 7) . Interestingly, inhibition of the ERK pathway led to a substantially enhanced but transient up-regulation of pMARCKS (at day 1), most notably in nAChR-expressing cells. This would indicate that the MAPK pathway may be suppressing the PKC-MARCKS pathway upon exposure to A␤.
Discussion
Acute-short-term application of A␤, or often a toxic C-terminal fragment of A␤ (A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) has been found to activate several signaling pathways (2), including the MAPK cascade (5, 6, 16, 36) . Here, we examined the impact of prolonged exposure to A␤ on intracellular signaling in a model cultured nerve cell system (differentiated clonal neuroblastoma cells) selectively expressing ␣4␤2-nAChRs, as defined high-affinity targets for A␤ (22) (23) (24) . The advantage of this model neuronal system is that the timeframe for the basic sequence of events in A␤ neurotoxicity, steps previously identified for a wide range of other neural systems, has been clearly delineated ( Fig. 8; Ref. 22 ). In addition, the presence of ␣4␤2-nAChRs was found to substantially sensitize the cells to A␤-induced oxidative stress and ultimately apoptosis (22) , essentially as a shift in the dose-response such that nanomolar A␤ was now toxic, whereas in the absence of nAChRs micromolar A␤ was required to induce toxicity. How this sensitization engages intracellular signaling pathways was the objective of the present study.
We found substantial ERK activation following nanomolar A␤ treatment of cells expressing ␣4␤2-nAChRs, as one of the earliest sensitization events connected with oxidative stress leading to frank neurotoxicity (Fig. 8 ). This is in contrast to the nominal ERK activation on treatment with nanomolar A␤ of cells without nAChRs or in other primary systems (e.g. Ref. 7) . CaMKII activation was also an early event, but it did not follow a pronounced, sustained timeline, unlike ERK activation which continued to increase substantially over several days. (There may remain maintained, Ca 2ϩ -independent CaMKII activity under these conditions, but the change in the level of pCaMKII was modest.) Activation of the JNK pathway by prolonged A␤ exposure in nerve cells expressing ␣4␤2-nAChRs, on the other hand, followed ERK activation, correlating with later phases in neurotoxicity. This finding confirms the central role of the JNK pathway in A␤ neurotoxicity, here using a defined, reconstituted neuronal system.
The subsequent oxidative stress induced by chronic A␤ was blocked by co-incubation with selective inhibitors of either the upstream MEK (for ERK) or JNK. As ERK and JNK are known to play important roles in hippocampus-based synaptic plasticity (10), learning (11, 13) and certain types of memory formation (12) (13) (14) , progressive activation of MAPKs following prolonged A␤ exposure suggests a molecular basis for the disruption of neuronal function in AD. For JNK, this extends to synaptic dys- . Note the significant increases following 3-day treatment with A␤ in the absence of target receptor (Mock). A␤-induced increases in PHF-Tau were compared in the absence or presence of U1026, a selective inhibitor of MEK, while A␤-induced increases in pFyn were compared in the absence or presence of PP2, a Src kinase family inhibitor. C and D, quantification of averaged immunoblot intensities, as compared with actin (loading control). Data are expressed as % (Ϯ S.E.) of untreated, mock-transfected controls (n ϭ 3 experiments). **, p Ͻ 0.01 for PHF-tau or pFyn levels in cells expressing ␣4␤2-nAChRs and treated with A␤ for 2 and 3 days when compared with untreated control. function (38) . Furthermore, this selective toxicity in the presence of ␣4␤2-nAChRs may contribute to the cholinergic deficit that occurs in Alzheimer disease.
The sensitization by ␣4␤2-nAChRs appears to be specific. In a preliminary study, it was found that the presence of ␣7-nAChRs did not lead to sensitization to A␤ toxicity. 3 Moreover, improvement in cognition has been found with activation of ␣7-nAChRs (e.g. 39), which have separately been shown to play a neuroprotective role against A␤ toxicity (40, 41) , possibly involving the PI3K/Akt anti-apoptotic pathway (42) . On the other hand, the up-regulation of ␣4␤2-nAChRs on chronic A␤ treatment may or may not play a role in the sensitization process. Certainly, ERK activation on chronic A␤ treatment well precedes the nAChR up-regulation, which was not significant until day 3 (see Ref. 22) . However, to address the role of up-regulation, it would require a means to prevent up-regulation in a controlled and defined way.
While investigating the possible mechanisms underlying the observed changes, it should be noted that MAP kinase path-ways are implicated in hyperphosphorylation of tau protein. Specifically, both ERK1 and ERK2 are capable of phosphorylating tau at several of the same sites as those found for PHF-tau (43) (44) (45) . By way of example, it has been demonstrated that microinjection of rat hippocampal primary neurons with purified ERK1 resulted in PHF-like tau hyperphosphorylation associated with compromised microtubule assembly (46) . Our findings showing that ERK activation precedes PHF-tau indicate that up-regulation of phospho-ERK might be one of the earliest signals in response to A␤ exposure, followed by formation of PHF-tau.
Besides A␤ and tau, another molecule that has been suggested to be the third member of this toxic triad is Fyn (21, 47) . Several lines of evidence suggest that Fyn kinase is involved in the synaptic and behavioral deficits associated with A␤ (48 -50) . Indeed, mature hippocampal cells from Fyn null (Ϫ/Ϫ) mice are protected against A␤-mediated toxicity (51) . Similarly, reducing or eliminating tau in a mouse model of AD significantly diminished behavioral deficits and improved survival, again strongly implicating tau in the mediation of the toxic effects of A␤ (52) . However, we found that Fyn activation was 3 G. Yoshikawa and R. A. Nichols, unpublished results. FIGURE 6. Alterations in the levels of pCaMKII and pCREB Fyn in response to prolonged exposure to A␤. A, progressive increases in the levels of pCaMKII and pCREB as compared with total CaMKII in differentiated NG108 -15 cells expressing ␣4␤2-nAChRs or not (Mock: mock-transfected) response to prolonged exposure to 100 nM A␤ . B and C, quantification of averaged immunoblot intensities, as compared with actin (loading control) for pCaMKII and pCREB, respectively. Data are expressed as % (ϮS.E.) of untreated, mock-transfected controls (n ϭ 3 experiments). *, p Ͻ 0.05 or **, p Ͻ 0.01 for pCaMKII or pCREB levels in cells expressing ␣4␤2-nAChRs and treated with A␤ for 2 and 3 days when compared with untreated control. increased with A␤ exposure, but not until 2-3 days, and the activation was entirely nAChR-independent. These results are in accordance with receptor-independent cross-talk between Fyn and tau during axonal myelination (53) . Thus, while Fyn activation parallels the appearance of PHF-tau, it is likely not downstream of the ERK activation and represents an independent, converging pathway for A␤ toxicity. This raises the unique possibility that the signaling sensitized by nAChRs acts in conjunction with a MAP kinase-independent pathway activated by A␤. Recently, it was found that Fyn is linked to A␤ signaling through cellular prion (37) , which, in turn, regulates surface expression of NMDA receptors. It would be of interest to consider the role of prion, as a separate target for A␤, in this scheme.
Based on our findings, we propose a link between receptor targets for A␤ and A␤-mediated neurotoxicity. Taken together, our results provide an insight into how different pathways might converge at a very early stage of Alzheimer disease, particularly in the presence of high-affinity nAChRs.
